FARLEY BROWN: Open Payments
NPI 1265467385 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 31 payments from 12 companies in 2025. Trend: 2023 $1,231 · 2024 $630 · 2025 $862
Food & beverage: $842Education: $20
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $243 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $241 |
| Novo Nordisk Inc | 3 | $165 |
| TOLMAR, INC. | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Exact Sciences Corporation | 1 | $20 |
| Gilead Sciences, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
Products named: CAPLYTA, Kerendia, Ozempic, JATENZO, The Cologuard Plus Collection Kit, REXULTI, AIRSUPRA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
